Today’s Research Reports on Trending Tickers: Exelixis and Sarepta Therapeutics
U.S. markets fell for the second consecutive session Wednesday as the tech sector’s struggles continued. The Dow Jones Industrial Average declined 0.04 percent to close at 23,848.42, while the S&P 500 Index fell 0.29 percent to close at 2,605.00. The Nasdaq Composite Index fell 0.85 percent to close at 6,949.23. On Wednesday, the Technology Select Sector SPDR fund dropped 0.67 percent, while the VanEck Vectors Semiconductor ETF fell 2.22 percent, closing more than 10 percent below its 52-week high.
"Tech is driving the news today," said Adam Sarhan, CEO of 50 Park Investments, according to CNBC. "What you’re seeing is a rotation out of tech and into some of the more fairly and under-valued areas of the market."
RDI Initiates Coverage on:
Sarepta Therapeutics, Inc.
Exelixis’ stock edged 0.36% lower Wednesday, to close the day at $22.36. The stock recorded a trading volume of 2,949,733 shares, which was above its three months average volume of 2,866,978 shares. In the last year, Exelixis’ shares have traded in a range of 18.03 – 32.50. The share price has gained 24.02% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $26.28 is below its 200-day moving average of $27.07. Shares of Exelixis are trading at a Price to Earnings ratio of 45.35. Shares of Exelixis have fallen roughly 13.33 percent in the past month and are down 26.45 percent year-to-date.
Access RDI’s Exelixis, Inc. Research Report at:
On Wednesday, shares of Sarepta Therapeutics recorded a trading volume of 1,906,496 shares, which was above the three months average volume of 1,589,893 shares. The stock ended the day 6.08% lower at 71.73. The share price has gained 154.90% from its 52 week low with a 52 week trading range of 28.14 – 84.37. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $69.61 is greater than its 200-day moving average of $57.99. Shares of Sarepta Therapeutics have gained roughly 14.27 percent in the past month and are up 28.92 percent year-to-date.
Access RDI’s Sarepta Therapeutics, Inc. Research Report at:
Our Actionable Research on Exelixis, Inc. (NASDAQ:EXEL) and Sarepta Therapeutics, Inc. (NASDAQ:SRPT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.